<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-21652" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Acute Febrile Neutrophilic Dermatosis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Majmundar</surname>
            <given-names>Vidit D.</given-names>
          </name>
          <aff>Civil Hospital Ahmedabad</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Saleh</surname>
            <given-names>Haitham M.</given-names>
          </name>
          <aff>Department of Dermatology, Ain Shams University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Baxi</surname>
            <given-names>Kalgi</given-names>
          </name>
          <aff>SMT NHL MEDICAL COLLEGE AND SVP HOSPITAL</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Vidit Majmundar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Haitham Saleh declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Kalgi Baxi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>1</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-21652.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Acute febrile neutrophilic dermatosis (AFND), also known as Sweet syndrome or Gomm-Button disease, manifests as erythematous plaques and papules, coupled with constitutional symptoms like fever and malaise. With an average onset age of 30 to 60 years and a female predominance, AFND displays a dense neutrophilic infiltrate histologically. Linked with various conditions, including infections, malignancies, inflammatory bowel disease, autoimmune disorders, pregnancy, and drugs, its cutaneous lesions present as tender, edematous, erythematous plaques, and occasionally bullous. Prednisone stands as the primary treatment, although dapsone, colchicine, and potassium iodide present as potential alternatives. This activity offers insights into AFND evaluation and management strategies and emphasizes the interprofessional team's role in optimizing patient care.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the etiology of acute febrile neutrophilic dermatosis.</p></list-item><list-item><p>Apply appropriate evaluation&#x000a0;methods for acute febrile neutrophilic dermatosis.</p></list-item><list-item><p>Implement evidence-based treatment strategies for acute febrile neutrophilic dermatosis.</p></list-item><list-item><p>Develop&#x000a0;interprofessional team strategies for improving care coordination and communication to advance the treatment of acute febrile neutrophilic dermatosis and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21652&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21652">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-21652.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Acute febrile neutrophilic dermatosis (AFND), also known as Sweet syndrome or Gomm Button disease, consists of&#x000a0;erythematous plaques and papules along with constitutional symptoms such as fever and malaise. The average age of onset is 30&#x000a0;to 60 years, and there is a female predominance. The disease is characterized histologically by a dense neutrophilic infiltrate. It is associated with several underlying diseases, including infections, malignancies, inflammatory bowel disease, autoimmune disorders, pregnancy, and drugs. Clinically, the cutaneous lesions present as tender, edematous, erythematous plaques and papules, which may occasionally be bullous. The most effective treatment is prednisone. Other potential treatments include dapsone, colchicine, and potassium iodide.<xref ref-type="bibr" rid="article-21652.r1">[1]</xref></p>
      </sec>
      <sec id="article-21652.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Etiologically, acute febrile neutrophilic dermatosis&#x000a0;can be classical or idiopathic, malignancy-associated, or drug-induced. Each of these ultimately leads to either unsolicited neutrophil proliferation or persistence in the blood and tissue, which is responsible for the clinical manifestations of the disease.</p>
        <p>
<bold>Classical</bold>
</p>
        <p>Classical Sweet syndrome, also known as idiopathic Sweet syndrome, accounts for the majority of Sweet syndrome cases. It is characterized by meeting the recognized diagnostic criteria without association with cancer or drug exposure.<xref ref-type="bibr" rid="article-21652.r1">[1]</xref> The occurrence of classical Sweet syndrome can be observed in various medical circumstances.</p>
        <p>Infections, including those affecting the upper respiratory tract and gastrointestinal system, have been found to be associated with the development of Sweet syndrome. Typically, this syndrome manifests within&#x000a0;1 to&#x000a0;3 weeks following the initial infection.&#x000a0;This syndrome&#x000a0;has also been associated with inflammatory bowel disease (Crohn disease and ulcerative colitis) and pregnancy.&#x000a0;There are infrequent and less conclusive connections observed with various infections such as HIV, tuberculosis, chlamydia, and viral hepatitis, as well as primary immunodeficiencies, autoimmune disorders including Beh&#x000e7;et syndrome, relapsing polychondritis, rheumatoid arthritis, sarcoidosis, autoimmune thyroid disease, connective tissue disorders such as systemic lupus erythematosus and dermatomyositis, and vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome.<xref ref-type="bibr" rid="article-21652.r2">[2]</xref></p>
        <p>VEXAS syndrome is an autoinflammatory condition that has been documented in adult males. Dermatological manifestations were observed in a significant proportion of patients diagnosed with VEXAS syndrome, as evidenced by a study conducted in 2022 that reviewed the literature and identified 126 out of 141 patients (89%) exhibiting such manifestations. The most commonly observed cutaneous manifestation appears to be the presence of lesions resembling those seen in Sweet syndrome, characterized by painful, erythematous, or violaceous nodules. Additional dermatological characteristics encompass the presence of cartilaginous engagement, including auditory and nasal chondritis, cutaneous vasculitis, and periorbital angioedema.<xref ref-type="bibr" rid="article-21652.r3">[3]</xref></p>
        <p>
<bold>Malignancy-associated</bold>
</p>
        <p>Malignancy-associated Sweet syndrome is responsible for a considerable proportion of instances of Sweet syndrome.<xref ref-type="bibr" rid="article-21652.r4">[4]</xref>&#x000a0;The occurrence of malignancy-associated Sweet syndrome in children seems to be predominantly observed in individuals aged&#x000a0;3 years and older.<xref ref-type="bibr" rid="article-21652.r5">[5]</xref>&#x000a0;Infants have been found to have rare cases of Sweet syndrome linked to cancer.<xref ref-type="bibr" rid="article-21652.r6">[6]</xref> The occurrence of Sweet syndrome can manifest prior to, subsequent to, or simultaneously with the development of a tumor.<xref ref-type="bibr" rid="article-21652.r7">[7]</xref> The occurrence of Sweet syndrome in individuals with a prior history of cancer may indicate the potential for disease relapse.<xref ref-type="bibr" rid="article-21652.r1">[1]</xref> The occurrence of Sweet syndrome is more commonly observed in conjunction with hematologic malignancies as opposed to solid tumors.<xref ref-type="bibr" rid="article-21652.r8">[8]</xref></p>
        <p>Acute myeloid leukemia (AML) is the neoplastic condition that exhibits the highest frequency of association with Sweet syndrome. AML represents 42% of the hematologic malignancies, whereas myeloproliferative disorders were identified as the second most prevalent malignancy category, accounting for 22%.<xref ref-type="bibr" rid="article-21652.r9">[9]</xref> Cancers of the genitourinary tract, breast, and digestive tract are the solid tumors most often linked to Sweet syndrome.<xref ref-type="bibr" rid="article-21652.r10">[10]</xref> Previous research conducted on individuals diagnosed with Sweet syndrome has revealed that those who are older, experience anemia, thrombocytopenia, and leukopenia, and do not exhibit arthralgias are more prone to developing malignancy-associated Sweet syndrome.<xref ref-type="bibr" rid="article-21652.r7">[7]</xref><xref ref-type="bibr" rid="article-21652.r8">[8]</xref>&#x000a0;Furthermore, it is worth noting that there is an increased risk of malignancy in patients who exhibit the histiocytoid or subcutaneous histologic variation of Sweet syndrome.<xref ref-type="bibr" rid="article-21652.r11">[11]</xref></p>
        <p>
<bold>Drug-induced</bold>
</p>
        <p>Multiple drugs may contribute to Sweet syndrome. Granulocyte-colony stimulating factor (G-CSF) is the most widely reported contributory medication.<xref ref-type="bibr" rid="article-21652.r12">[12]</xref> It has been documented that checkpoint inhibitor treatment can cause neutrophilic dermatoses, such as Sweet syndrome, brought on by ipilimumab therapy.<xref ref-type="bibr" rid="article-21652.r13">[13]</xref> Sweet syndrome often manifests around two weeks following drug exposure in individuals with no previous record of exposure to the causative substance.<xref ref-type="bibr" rid="article-21652.r14">[14]</xref> Reexposure to the initiating substance frequently causes a recurrence.<xref ref-type="bibr" rid="article-21652.r1">[1]</xref> Anecdotal case reports suggest an association with antibiotics, antiepileptics, nonsteroidal antiinflammatories, retinoids, and diuretics. However, the causal association has not been established by rechallenge.<xref ref-type="bibr" rid="article-21652.r1">[1]</xref><xref ref-type="bibr" rid="article-21652.r15">[15]</xref></p>
      </sec>
      <sec id="article-21652.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>AFND&#x000a0;is uncommon, found worldwide, and has a 4:1&#x000a0;female-to-male predominance. The average age of onset is 30&#x000a0;to 60 years, but it can occur in infants and older people. The observed gender disparity in Sweet syndrome does not seem to apply to the pediatric population.<xref ref-type="bibr" rid="article-21652.r5">[5]</xref> Sweet syndrome does not appear to have a clear racial preference. At least half of all patients have an identifiable underlying association. Internal malignancy is found in 15% to 30% of cases, and hematologic malignancy is more common than solid organ cancer. Twenty-five percent&#x000a0;of patients have a preceding infection, and 10% have exposure to a potentially causative drug.<xref ref-type="bibr" rid="article-21652.r16">[16]</xref></p>
      </sec>
      <sec id="article-21652.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The underlying pathophysiology of acute febrile neutrophilic dermatosis is unknown, but a few hypotheses exist. The etiology of this condition has been postulated to involve many factors, such as hypersensitivity reactions, dysregulation of cytokines, and hereditary predisposition.</p>
        <p>
<bold>Hypersensitivity Reaction</bold>
</p>
        <p>An immunological response to bacterial, viral, neoplastic, or other antigens can influence the development of Sweet syndrome. This immune response stimulates the generation of cytokines that facilitate neutrophil activation and infiltration. The notion is somewhat supported by the good response observed in systemic glucocorticoid treatment and the reported improvement of Sweet syndrome after treating bacterial infections or malignancies.<xref ref-type="bibr" rid="article-21652.r17">[17]</xref></p>
        <p>
<bold>Cytokine Dysregulation</bold>
</p>
        <p>Dysregulation of cytokine secretion (including interleukin-1 [IL-1], G-CSF, granulocyte-macrophage colony-stimulating factor, and interferon-gamma) resulting in dysfunction of neutrophil apoptosis is one hypothesis.<xref ref-type="bibr" rid="article-21652.r18">[18]</xref>&#x000a0;A defect in the transcriptional regulation of the hematopoietic&#x000a0;protein tyrosine phosphatase nonreceptor type 6 (PTPN6) has also been found to contribute to the pathogenesis of neutrophilic dermatoses.<xref ref-type="bibr" rid="article-21652.r19">[19]</xref> Alterations of proinflammatory cell signaling pathways and cytokine production in a genetically predisposed individual are considered central to the pathogenesis of AFND. Ultimately, these alterations affect neutrophil proliferation, migration, and destruction in the skin and other tissues.</p>
        <p>Tissue neutrophil levels are a function of infectious triggers for neutrophil proliferation and migration, bone marrow granulopoiesis, storage and release, transendothelial migration, and the rate of neutrophil destruction. Abnormality in any of these steps could influence the development and progression of AFND. Migration of neutrophils to the tissue in situations of cell stress is a normal immunological response; however, the loss of control over this process in AFND appears to be largely cytokine-mediated. Most commonly, IL-1, IL-3, IL-6, and IL-8 are elevated in AFND. Moreover, elevated levels of G-CSF have also been noted in patients with AFND.</p>
        <p>Various tissues, including the endothelium and macrophages, produce G-CSF. Additionally, increased production of G-CSF is noted in multiple malignancies. In sum, it may be hypothesized that abnormally increased production of G-CSF or increased sensitivity to normal levels of G-CSF could be the unifying mechanism of all three variants of AFND.</p>
        <p>
<bold>Genetic Factors</bold>
</p>
        <p>Defects in the transcriptional regulation of the <italic toggle="yes">PTPN6</italic> gene and mutations of the <italic toggle="yes">MEFV</italic> gene associated with familial Mediterranean fever have been implicated in the pathogenesis of AFND.<xref ref-type="bibr" rid="article-21652.r1">[1]</xref><xref ref-type="bibr" rid="article-21652.r20">[20]</xref><xref ref-type="bibr" rid="article-21652.r21">[21]</xref> The association between <italic toggle="yes">HLA-B54</italic> and Sweet syndrome has been observed in Japanese patients.<xref ref-type="bibr" rid="article-21652.r22">[22]</xref></p>
        <p>Antibodies against neutrophilic cytoplasmic antigens have been seen in certain individuals diagnosed with Sweet syndrome.<xref ref-type="bibr" rid="article-21652.r23">[23]</xref> Nevertheless, the potential significance of these antibodies in causing disease has yet to be determined. Additional research is required to elucidate the underlying mechanisms responsible for the pathogenesis of Sweet syndrome.</p>
      </sec>
      <sec id="article-21652.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>A 4-mm punch biopsy is usually enough to produce a tissue specimen for histologic evaluation in patients with inflammatory papules or plaques. Microbial pathology stains should be performed since the infection may resemble Sweet syndrome. In addition, a second 4-mm punch biopsy is obtained for bacterial, fungal, and mycobacterial cultures. A swab specimen can also be sent for culture if pustules are detected. An excisional biopsy is preferred in patients with nodules suggestive of subcutaneous Sweet syndrome (a variant in which the pathologic process is primarily located in the subcutaneous fat) because it provides a more generous sample of the subcutaneous fat, which may aid in the interpretation of the histologic findings.</p>
        <p>The histopathological features usually depend upon the type of lesion sampled:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Epidermis:</bold> Usually insignificant; however, the occasional spillover of dermal neutrophils may occur, producing subcorneal pustules. There can be epidermal spongiosis. Sometimes, reticular degeneration of the keratinocytes may lead to frank intraepidermal or subepidermal vesiculation.</p>
          </list-item>
          <list-item>
            <p><bold>Dermis:</bold>&#x000a0;Diffuse nodular and perivascular neutrophilic infiltrate without evidence of vasculitis; leukocytoclasia, with endothelial swelling without fibrinoid necrosis, is a usual finding. Vasculitis may be seen as a secondary epiphenomenon in this setting.</p>
          </list-item>
          <list-item>
            <p><bold>Subcutaneous fat:</bold>&#x000a0;Extension of dermal infiltrate into the subcutis may lead to septal or lobular panniculitis. Isolated neutrophilic panniculitis has also been observed.</p>
          </list-item>
        </list>
        <p>Histopathological variants:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Histocytoid:</bold>&#x000a0;An infiltrate composed of immature spindle-shaped histiocyte-like cells. Immunohistochemistry shows the presence of myeloperoxidase activity in these cells. They have to be closely differentiated from leukemia cutis.</p>
          </list-item>
          <list-item>
            <p><bold>Lymphocytic:</bold>&#x000a0;The infiltrate is predominantly lymphocytic, usually associated with myelodysplasia.</p>
          </list-item>
          <list-item>
            <p><bold>Eosinophilic:</bold>&#x000a0;The infiltrate is rich with eosinophils. A case has been observed in the setting of enteropathy-associated T-cell lymphoma.<xref ref-type="bibr" rid="article-21652.r1">[1]</xref><xref ref-type="bibr" rid="article-21652.r11">[11]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-21652.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>The term&#x000a0;AFND is used to describe the occurrence of temperatures over 38&#x000b0;C in individuals with Sweet syndrome. The majority of patients diagnosed with drug-induced Sweet syndrome often experience fever. In contrast, there is a subset of individuals with classical or malignancy-associated disease where fever may be absent in 10% to 20% of cases. Additional symptoms commonly observed in Sweet syndrome include arthralgias, malaise, headaches, and myalgias. Alongside the sudden appearance of the painful inflammatory papules, plaques, and nodules that are characteristic of Sweet syndrome, there may be the emergence of additional clinical characteristics:</p>
        <p>
<bold>Cutaneous Disease</bold>
</p>
        <p>The classical clinical appearance is erythematous, tender, nonpruritic papules, nodules, and plaques with predominantly head, neck, and upper trunk distribution patterns. The plaques are often studded with multiple closely grouped translucent papules, giving the illusion of vesiculation. These pseudo-vesicles and pseudo-pustules impart a mamillated appearance to the surface of the plaques and are considered one of the suggestive manifestations of AFND. Subsequent ulceration may occur, which resembles a superficial pyoderma gangrenosum described in association with acute myeloid leukemia. Papulonodular lesions of the lower limbs closely resemble erythema nodosum and can be differentiated histopathologically.&#x000a0;Sweet syndrome patients report soreness or burning from cutaneous lesions.</p>
        <p>Less often observed manifestations of Sweet syndrome include:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Neutrophilic dermatosis of the dorsal hands:</bold>&#x000a0;Characterized by bluish violaceous or hemorrhagic papules, bullae, and nodules on the dorsal hands. It may be accompanied by typical lesions of Sweet syndrome in other areas of the body. This variant may have a more significant association with occult or hematological malignancies. It closely mimics a bullous pyoderma gangrenosum.</p>
          </list-item>
          <list-item>
            <p><bold>Subcutaneous Sweet syndrome:</bold>&#x000a0;Presents with erythema nodosum-like lesions on the shins. Notably, the location of neutrophilic infiltration occurs inside the subcutaneous adipose tissue, as opposed to the dermis.<xref ref-type="bibr" rid="article-21652.r1">[1]</xref><xref ref-type="bibr" rid="article-21652.r24">[24]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Bullous Sweet syndrome: </bold>Characterized by&#x000a0;vesicles and flaccid bullae, Bullous Sweet syndrome is rare and&#x000a0;can cause pyoderma gangrenosum-like ulceration, usually in hematologic malignancies.<xref ref-type="bibr" rid="article-21652.r4">[4]</xref></p>
          </list-item>
        </list>
        <p>Furthermore, there have been documented cases of patients presenting with Sweet syndrome that closely resemble necrotizing fasciitis, referred to as necrotizing Sweet syndrome<xref ref-type="bibr" rid="article-21652.r25">[25]</xref>. Patients exhibit pyrexia, accompanied by the progressive development of erythematous to violaceous plaques. The manifestation of extensive cellulitis-like plaques has been identified as an infrequent clinical sign of Sweet syndrome. The designation "giant cellulitis-like Sweet syndrome" was employed to describe the occurrence of extensive infiltrating inflammatory plaques and bullae in three patients who met the diagnostic criteria for Sweet syndrome.<xref ref-type="bibr" rid="article-21652.r26">[26]</xref> The phenomenon of pathergy, wherein a cutaneous lesion is triggered by minor trauma, is demonstrated in AFND in common with other neutrophilic dermatoses. The probable mechanism could be the destruction of endothelial cells, cytokine dysregulation, and resultant neutrophil activation.</p>
        <p>
<bold>Oral Disease</bold>
</p>
        <p>The occurrence of oral manifestations in classical Sweet syndrome is infrequent. Nevertheless, it is worth noting that around 12% of individuals diagnosed with Sweet syndrome in connection with hematologic malignancies experience the development of oral ulcers as a manifestation of the disease, specifically on the buccal mucosa or tongue.<xref ref-type="bibr" rid="article-21652.r1">[1]</xref> Further documented oral observations encompass bullae, vesicles, gingival hyperplasia, necrotizing ulcerative periodontitis, nodules, papules, pustules, and swelling of the tongue.<xref ref-type="bibr" rid="article-21652.r27">[27]</xref></p>
        <p>
<bold>Extracutaneous Disease</bold>
</p>
        <p>Sweet syndrome is characterized by the potential for neutrophilic infiltration into various organ systems, including the eye, lungs, muscles, bone, liver, spleen, heart, kidneys, central nervous system, and gastrointestinal tract. Such infiltration may give rise to symptoms particular to the extracutaneous site of inflammation.</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Eye:</bold>&#x000a0;Ocular inflammation is a prevalent extracutaneous presentation, manifesting in 17% to 72% of patients diagnosed with the classical variant. Conjunctivitis, episcleritis, scleritis, limbal nodules, peripheral ulcerative keratitis, iritis, glaucoma, dacryoadenitis, and choroiditis are all illustrative instances of ocular manifestations.<xref ref-type="bibr" rid="article-21652.r28">[28]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Musculoskeletal system:</bold>&#x000a0;An additional common site of extracutaneous involvement in the body, where arthralgias, arthritis, and myalgias can manifest.</p>
          </list-item>
          <list-item>
            <p><bold>Central nervous system:</bold>&#x000a0;Encephalitis, aseptic meningitis</p>
          </list-item>
          <list-item>
            <p><bold>Pulmonary system:</bold>&#x000a0;Neutrophilic alveolitis, pleural effusions, airway obstruction</p>
          </list-item>
          <list-item>
            <p><bold>Cardiovascular system:</bold>&#x000a0;Myocarditis, aortitis and aortic stenosis, coronary artery occlusion</p>
          </list-item>
          <list-item>
            <p><bold>Liver: H</bold>epatitis, hepatomegaly</p>
          </list-item>
          <list-item>
            <p><bold>Intestines:</bold>&#x000a0;Neutrophilic inflammation of the intestines</p>
          </list-item>
          <list-item>
            <p><bold>Spleen:</bold>&#x000a0;Splenomegaly</p>
          </list-item>
          <list-item>
            <p><bold>Kidneys: </bold>Mesangial glomerulonephritis, hematuria, proteinuria</p>
          </list-item>
          <list-item>
            <p><bold>Bone:</bold>&#x000a0;Sterile osteomyelitis</p>
          </list-item>
        </list>
        <p>Additionally, there have been reports of the occurrence of systemic inflammatory response syndrome (SIRS) in conjunction with Sweet syndrome.<xref ref-type="bibr" rid="article-21652.r29">[29]</xref></p>
      </sec>
      <sec id="article-21652.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>There are no specific diagnostic tests for AFND. Su and Liu proposed the diagnostic criteria for Sweet syndrome.<xref ref-type="bibr" rid="article-21652.r30">[30]</xref></p>
        <p>
<bold>Major Criteria </bold>
</p>
        <p>Both of the following must be present to establish a diagnosis of Sweet syndrome:<bold/></p>
        <list list-type="bullet">
          <list-item>
            <p>Abrupt onset of typical cutaneous lesions</p>
          </list-item>
          <list-item>
            <p>Histopathology consistent with Sweet syndrome</p>
          </list-item>
        </list>
        <p>
<bold>Minor Criteria </bold>
</p>
        <p>For diagnostic confirmation of Sweet syndrome, at least 2 minor clinical features should be present.<bold/></p>
        <list list-type="bullet">
          <list-item>
            <p>Preceded by one of the associated infections or vaccinations, accompanied by one of the associated malignancies, drug exposure, or pregnancy</p>
          </list-item>
          <list-item>
            <p>Fever &#x0003e;38&#x000ba; C</p>
          </list-item>
          <list-item>
            <p>Three out of these 4 abnormal laboratory values at presentation, including 1) Erythrocyte sedimentation rate (ESR) &#x0003e;20 mm/h; 2)&#x000a0;Leukocytes &#x0003e;8000 mm<sup>3</sup>/h;&#x000a0;3) Neutrophils &#x0003e;70%;&#x000a0;4) Elevated C-reactive protein (CRP)&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Dramatic response to systemic corticosteroids or potassium iodide (KI)</p>
          </list-item>
        </list>
        <p>Based on these criteria, the essential investigations include a skin biopsy, complete blood count, ESR, CRP, liver, and renal function tests. Additional tests include thyroid function tests, rheumatoid factor, and antistreptolysin-O antibody titers. The most prevalent laboratory abnormality in Sweet syndrome patients is peripheral leukocytosis with neutrophilia.</p>
        <p>Neutrophilia is found in the great majority of patients with classical Sweet syndrome, as well as in a considerable proportion of patients with cancer-related and drug-induced illnesses. Anemia and platelet abnormalities are common in patients with Sweet syndrome caused by cancer or medications, but they are seldom found in patients with classic Sweet syndrome. Abnormalities in the full metabolic panel and urine may indicate hepatic or renal involvement.<xref ref-type="bibr" rid="article-21652.r16">[16]</xref></p>
        <p>A complete lymph node examination, examination of breasts and pelvis in females and prostate and testicles in males, sigmoidoscopy, and positron emission tomography (PET) scans comprise the workup to rule out occult malignancy. Malignancy testing should be considered only when there is a reasonable clinical suspicion for an underlying malignancy (eg, constitutional symptoms such as weight loss) and no other explanation for a Sweet syndrome diagnosis (eg, pregnancy, drug exposure, recent infection, inflammatory bowel disease, rheumatoid arthritis). Although elevated levels of anti-neutrophil cytoplasmic antibodies (C-ANCA) have been noted, they are no longer considered significant.<xref ref-type="bibr" rid="article-21652.r1">[1]</xref><xref ref-type="bibr" rid="article-21652.r30">[30]</xref></p>
      </sec>
      <sec id="article-21652.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>To achieve illness control, the majority of patients require systemic medication. Patients who appear with a few isolated skin lesions (eg, &#x0003c;5% of body surface area) and no systemic symptoms, on the other hand, may react well to local corticosteroid therapy. In individuals with broad cutaneous lesions, local treatment may be utilized in addition to systemic glucocorticoids or other systemic medicines. This is frequently&#x000a0;conducted to lessen reliance on systemic medications and speed up lesion healing.</p>
        <p>
<bold>Systemic Glucocorticoids</bold>
</p>
        <p>The immediate and dramatic response of Sweet syndrome to systemic glucocorticoids, as recorded in several case reports and case series, validates their place as the therapy of choice for this condition. Including the response to systemic glucocorticoids in the diagnostic criteria reflects the high chance of therapeutic effectiveness. Systemic glucocorticoids are beneficial for both cutaneous and extracutaneous Sweet syndrome signs. Adults are often started on oral prednisone at a dose of 0.5 to 1 mg/kg per day. Symptoms typically recover after 48 hours, and skin lesions disappear within&#x000a0;1 to&#x000a0;2 weeks.<xref ref-type="bibr" rid="article-21652.r31">[31]</xref> Once disease control is achieved, tapering prednisone over a 4- to 6-week period should be attempted.</p>
        <p>
<bold>Topical and Intralesional Corticosteroids</bold>
</p>
        <p>Topical corticosteroids with high potency (eg, Clobetasol 0.05% ointment) and intralesional corticosteroid injections are used. For&#x000a0;2 to&#x000a0;3 weeks, topical corticosteroids are typically used twice daily on the afflicted area. Occlusion therapy may hasten the response to therapy. Intralesional therapy is effective for thick plaques on the trunk or extremities that do not respond entirely to topical therapy.</p>
        <p>
<bold>Colchicine, Dapsone, and Potassium Iodide</bold>
</p>
        <p>These medicines,&#x000a0;less commonly used than systemic glucocorticoids, are utilized as first-line therapeutics when it is preferable to avoid systemic glucocorticoid therapy due to patient comorbidities or other circumstances. Treatment with low-dose steroids may have to be continued for a longer time to prevent exacerbations. If remission is not achieved within 3 months, a second-line steroid-sparing agent must be added.</p>
        <p>The main second-line steroid-sparing agents include dapsone (50-100 mg/day), KI (300 mg 3 times a day), and colchicine (0.5 mg 3 times a day). A baseline G6PD activity should be done in patients before starting dapsone. Miscellaneous drugs that have been reported to be efficacious in various studies include cyclophosphamide, cyclosporine, thalidomide, clofazimine,&#x000a0;intravenous immunoglobulin, and tumor&#x000a0;necrosis factor&#x02013;&#x003b1;&#x000a0;antagonists.<xref ref-type="bibr" rid="article-21652.r1">[1]</xref></p>
        <p>Clinical evidence suggests that pulse glucocorticoid therapy may be useful in treating severe Sweet syndrome or Sweet syndrome that does not respond adequately to other medications.<xref ref-type="bibr" rid="article-21652.r32">[32]</xref>&#x000a0;Adults may be given intravenous methylprednisolone at doses ranging from 500 to 1000 mg per day for&#x000a0;3 to&#x000a0;5 days. An oral glucocorticoid taper or another systemic immunosuppressive medication is used after treatment. In refractory instances, newer case reports suggest that rituximab, adalimumab, infliximab, tocilizumab, ustekinumab, and the Janus kinase (JAK) inhibitor baricitinib may be beneficial.<xref ref-type="bibr" rid="article-21652.r33">[33]</xref><xref ref-type="bibr" rid="article-21652.r34">[34]</xref><xref ref-type="bibr" rid="article-21652.r35">[35]</xref><xref ref-type="bibr" rid="article-21652.r36">[36]</xref><xref ref-type="bibr" rid="article-21652.r37">[37]</xref></p>
      </sec>
      <sec id="article-21652.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Infection is one of the most significant illnesses to consider in a patient with Sweet syndrome&#x02013;like&#x000a0;clinical or histologic findings. As with Sweet syndrome, bacterial sepsis can cause fever, leukocytosis, and skin lesions with neutrophil-dense infiltrates. Furthermore, Sweet syndrome lesions can resemble local bacterial, fungal, or atypical mycobacterial diseases.</p>
        <p>The results of a retrospective study in which fluorescence&#x000a0;in situ hybridization (FISH) was performed on preserved cutaneous specimens from&#x000a0;5 of&#x000a0;6 patients with hematologic malignancy&#x02013;associated histiocytoid Sweet syndrome suggest that the clinicopathologic findings of histiocytoid Sweet syndrome may be particularly difficult to distinguish from leukemia cutis.<xref ref-type="bibr" rid="article-21652.r38">[38]</xref> Cytogenic abnormalities in lesional skin matched those found in earlier bone marrow biopsy specimens in&#x000a0;4 of the&#x000a0;5 patients, implying that these&#x000a0;4 individuals had leukemia cutis. More research is needed to understand the usefulness of FISH analysis in distinguishing between histiocytoid Sweet syndrome and leukemia cutis.</p>
        <p>The clinical differential diagnosis for&#x000a0;Sweet syndrome is based on lesion morphology. Data from the clinical history, physical examination, pathology findings, and microbiological investigations might help differentiate Sweet syndrome from other conditions, including:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Erythematous, edematous plaques</bold>: Cutaneous infection (bacterial, fungal, and mycobacterial); urticaria and urticarial vasculitis; drug eruptions; halogenoderma (eg, bromoderma, iododerma); other neutrophilic dermatoses (eg, pyoderma gangrenosum, neutrophilic eccrine hidradenitis, Beh&#x000e7;et syndrome, cutaneous metastatic Crohn disease)</p>
          </list-item>
          <list-item>
            <p><bold>Bullous lesions</bold>: Bullous leukocytoclastic vasculitis; bullous pyoderma gangrenosum; autoimmune bullous diseases (eg, bullous pemphigoid, bullous systemic lupus erythematosus, inflammatory epidermolysis bullosa acquisita, linear&#x000a0;immunoglobulin A&#x000a0;bullous dermatosis); infection with bullous and hemorrhagic or necrotic changes (eg, bullous cellulitis, vessel invasive infections such as aspergillosis, ecthyma gangrenosum)</p>
          </list-item>
          <list-item>
            <p><bold>Nodules (including subcutaneous Sweet syndrome)</bold>: Cutaneous infection (eg, deep fungal infection, Majocchi's granuloma, atypical mycobacterial infection); subcutaneous sarcoidosis; erythema nodosum; vasculitis (particularly medium-vessel vasculitis such as cutaneous polyarteritis nodosa); malignancy (eg, lymphoma cutis, leukemia cutis, metastatic carcinoma)<xref ref-type="bibr" rid="article-21652.r1">[1]</xref><xref ref-type="bibr" rid="article-21652.r21">[21]</xref><xref ref-type="bibr" rid="article-21652.r39">[39]</xref><xref ref-type="bibr" rid="article-21652.r40">[40]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-21652.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The cutaneous lesions of AFND, or Sweet syndrome, eventually show spontaneous resolution along with the associated extracutaneous manifestations. However, periodic exacerbations may occur, representing underlying paraneoplastic conditions. In a patient with a treated malignancy, the recurrence of lesions in Sweet syndrome heralds a relapse. In the case of local cutaneous complications such as scarring and acquired cutis laxa, the prognosis is poor as they seldom respond to any modality.<xref ref-type="bibr" rid="article-21652.r41">[41]</xref></p>
        <p>In about 30% of cases, the skin lesions show spontaneous resolution within 3 months. However, a fluctuating course with relapse and remission is more frequently observed. Relapse can occur after reducing or discontinuing systemic glucocorticoids or other therapy, and it is more likely in patients with malignancy-related illnesses. Sweet syndrome recurrences occur in around 30% of patients with classical Sweet syndrome. In the presence of an underlying hematologic malignancy, the recurrence rate may be as high as 69%.<xref ref-type="bibr" rid="article-21652.r42">[42]</xref></p>
      </sec>
      <sec id="article-21652.s12" sec-type="Complications">
        <title>Complications</title>
        <p>Even though lesions usually resolve with mild post-inflammatory hyperpigmentation, various localized complications, such as scarring in the case of ulcerative lesions and atrophy in cases of panniculitis, have been observed. Postinflammatory elastolysis presenting as acquired cutis laxa, also called Marshal syndrome, is a frequently encountered finding.<xref ref-type="bibr" rid="article-21652.r41">[41]</xref></p>
      </sec>
      <sec id="article-21652.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>In patients diagnosed with AFND or Sweet syndrome, detailed counseling regarding the need to rule out underlying systemic diseases or malignancies should be carried out. Regular consultation with the dermatologist is recommended. In patients with treated malignancy, the reappearance of lesions should not be ignored, as they can signal a relapse.<xref ref-type="bibr" rid="article-21652.r24">[24]</xref></p>
      </sec>
      <sec id="article-21652.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Sweet syndrome is one of the great mimickers in dermatology. The key to diagnosing this syndrome is to have a high index of suspicion. Prompt referral to a dermatologist for tender erythematous papulonodular lesions with fever, which show an inadequate therapeutic response to analgesics and antibiotics, is necessary. In suspected cases, primary&#x000a0;clinicians should&#x000a0;obtain routine investigations such as a complete blood count, ESR, and CRP. Sweet syndrome heralds an underlying infectious, immunological, or malignant disease; hence, prompt diagnosis and a thorough evaluation by an interprofessional team are necessary for ruling out underlying systemic illnesses.<xref ref-type="bibr" rid="article-21652.r1">[1]</xref><xref ref-type="bibr" rid="article-21652.r24">[24]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-21652.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21652&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21652">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/skin-problems-and-treatments/acute-febrile-neutrophilic-dermatosis-sweet-syndrome-gomm-button-disease/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=21652">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/21652/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=21652">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-21652.s16">
        <fig id="article-21652.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Neutrophic Dermatosis <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dermnetnz.org/images">DermNet New Zealand</ext-link></p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="neutrophic__dermatosis" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-21652.s17">
        <title>References</title>
        <ref id="article-21652.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cohen</surname>
                <given-names>PR</given-names>
              </name>
            </person-group>
            <article-title>Sweet's syndrome--a comprehensive review of an acute febrile neutrophilic dermatosis.</article-title>
            <source>Orphanet J Rare Dis</source>
            <year>2007</year>
            <month>Jul</month>
            <day>26</day>
            <volume>2</volume>
            <fpage>34</fpage>
            <pub-id pub-id-type="pmid">17655751</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21652.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gray</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Bock</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ziegler</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Wargon</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Neonatal Sweet syndrome: a potential marker of serious systemic illness.</article-title>
            <source>Pediatrics</source>
            <year>2012</year>
            <month>May</month>
            <volume>129</volume>
            <issue>5</issue>
            <fpage>e1353</fpage>
            <page-range>e1353-9</page-range>
            <pub-id pub-id-type="pmid">22508923</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21652.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sterling</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Duncan</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Philippidou</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Salisbury</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Kulasekararaj</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Basu</surname>
                <given-names>TN</given-names>
              </name>
            </person-group>
            <article-title>VEXAS syndrome (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) for the dermatologist.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2023</year>
            <month>Dec</month>
            <volume>89</volume>
            <issue>6</issue>
            <fpage>1209</fpage>
            <page-range>1209-1214</page-range>
            <pub-id pub-id-type="pmid">35121074</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21652.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Raza</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kirkland</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Shortridge</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Freter</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Insight into Sweet's syndrome and associated-malignancy: a review of the current literature.</article-title>
            <source>Int J Oncol</source>
            <year>2013</year>
            <month>May</month>
            <volume>42</volume>
            <issue>5</issue>
            <fpage>1516</fpage>
            <page-range>1516-22</page-range>
            <pub-id pub-id-type="pmid">23546524</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21652.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Halpern</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Salim</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Pediatric sweet syndrome: case report and literature review.</article-title>
            <source>Pediatr Dermatol</source>
            <year>2009</year>
            <season>Jul-Aug</season>
            <volume>26</volume>
            <issue>4</issue>
            <fpage>452</fpage>
            <page-range>452-7</page-range>
            <pub-id pub-id-type="pmid">19689524</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21652.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Uihlein</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Brandling-Bennett</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Lio</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Liang</surname>
                <given-names>MG</given-names>
              </name>
            </person-group>
            <article-title>Sweet syndrome in children.</article-title>
            <source>Pediatr Dermatol</source>
            <year>2012</year>
            <season>Jan-Feb</season>
            <volume>29</volume>
            <issue>1</issue>
            <fpage>38</fpage>
            <page-range>38-44</page-range>
            <pub-id pub-id-type="pmid">22011318</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21652.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marcoval</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;n-Callizo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Valent&#x000ed;-Medina</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bonfill-Ort&#x000ed;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;nez-Molina</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Sweet syndrome: long-term follow-up of 138 patients.</article-title>
            <source>Clin Exp Dermatol</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>41</volume>
            <issue>7</issue>
            <fpage>741</fpage>
            <page-range>741-6</page-range>
            <pub-id pub-id-type="pmid">27663147</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21652.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nelson</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Noe</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>McMahon</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Gowda</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ashchyan</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Perl</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>James</surname>
                <given-names>WD</given-names>
              </name>
              <name>
                <surname>Micheletti</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Rosenbach</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Sweet syndrome in patients with and without malignancy: A retrospective analysis of 83 patients from a tertiary academic referral center.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>78</volume>
            <issue>2</issue>
            <fpage>303</fpage>
            <page-range>303-309.e4</page-range>
            <pub-id pub-id-type="pmid">29107342</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21652.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cohen</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Talpaz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kurzrock</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Malignancy-associated Sweet's syndrome: review of the world literature.</article-title>
            <source>J Clin Oncol</source>
            <year>1988</year>
            <month>Dec</month>
            <volume>6</volume>
            <issue>12</issue>
            <fpage>1887</fpage>
            <page-range>1887-97</page-range>
            <pub-id pub-id-type="pmid">3058878</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21652.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cohen</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Holder</surname>
                <given-names>WR</given-names>
              </name>
              <name>
                <surname>Tucker</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Kono</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kurzrock</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Sweet syndrome in patients with solid tumors.</article-title>
            <source>Cancer</source>
            <year>1993</year>
            <month>Nov</month>
            <day>01</day>
            <volume>72</volume>
            <issue>9</issue>
            <fpage>2723</fpage>
            <page-range>2723-31</page-range>
            <pub-id pub-id-type="pmid">8402496</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21652.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ghoufi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ortonne</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ingen-Housz-Oro</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Barhoumi</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Begon</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Haioun</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pautas</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Beckerich</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Robin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wolkenstein</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Cordonnier</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Chosidow</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Toma</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Histiocytoid Sweet Syndrome Is More Frequently Associated With Myelodysplastic Syndromes Than the Classical Neutrophilic Variant: A Comparative Series of 62 Patients.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>95</volume>
            <issue>15</issue>
            <fpage>e3033</fpage>
            <pub-id pub-id-type="pmid">27082547</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21652.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>White</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Mufti</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Salisbury</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>du Vivier</surname>
                <given-names>AW</given-names>
              </name>
            </person-group>
            <article-title>Cutaneous manifestations of granulocyte colony-stimulating factor.</article-title>
            <source>Clin Exp Dermatol</source>
            <year>2006</year>
            <month>Mar</month>
            <volume>31</volume>
            <issue>2</issue>
            <fpage>206</fpage>
            <page-range>206-7</page-range>
            <pub-id pub-id-type="pmid">16487091</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21652.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ravi</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Maloney</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Worswick</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Neutrophilic dermatoses as adverse effects of checkpoint inhibitors: A review.</article-title>
            <source>Dermatol Ther</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>32</volume>
            <issue>5</issue>
            <fpage>e13074</fpage>
            <pub-id pub-id-type="pmid">31444856</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21652.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Choe</surname>
                <given-names>YH</given-names>
              </name>
            </person-group>
            <article-title>EPONYM. Sweet syndrome.</article-title>
            <source>Eur J Pediatr</source>
            <year>2010</year>
            <month>Dec</month>
            <volume>169</volume>
            <issue>12</issue>
            <fpage>1439</fpage>
            <page-range>1439-44</page-range>
            <pub-id pub-id-type="pmid">20445990</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21652.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rajakulenthiran</surname>
                <given-names>TG</given-names>
              </name>
              <name>
                <surname>Amarasena</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kelly</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Silva</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>The importance of skin biopsies: Sweet syndrome as a differential for 'acute painful red rash' in a patient with normal neutrophils and polymyalgia rheumatica on glucocorticoids.</article-title>
            <source>Clin Med (Lond)</source>
            <year>2020</year>
            <month>Mar</month>
            <volume>20</volume>
            <issue>Suppl 2</issue>
            <fpage>s25</fpage>
            <pub-id pub-id-type="pmid">32409350</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21652.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rochet</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Chavan</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Cappel</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Wada</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Gibson</surname>
                <given-names>LE</given-names>
              </name>
            </person-group>
            <article-title>Sweet syndrome: clinical presentation, associations, and response to treatment in 77 patients.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2013</year>
            <month>Oct</month>
            <volume>69</volume>
            <issue>4</issue>
            <fpage>557</fpage>
            <page-range>557-64</page-range>
            <pub-id pub-id-type="pmid">23891394</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21652.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Voelter-Mahlknecht</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bauer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Metzler</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Fierlbeck</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rassner</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Bullous variant of Sweet's syndrome.</article-title>
            <source>Int J Dermatol</source>
            <year>2005</year>
            <month>Nov</month>
            <volume>44</volume>
            <issue>11</issue>
            <fpage>946</fpage>
            <page-range>946-7</page-range>
            <pub-id pub-id-type="pmid">16336530</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21652.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kawakami</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ohashi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kawa</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Takahama</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ito</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Soma</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Mizoguchi</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Elevated serum granulocyte colony-stimulating factor levels in patients with active phase of sweet syndrome and patients with active behcet disease: implication in neutrophil apoptosis dysfunction.</article-title>
            <source>Arch Dermatol</source>
            <year>2004</year>
            <month>May</month>
            <volume>140</volume>
            <issue>5</issue>
            <fpage>570</fpage>
            <page-range>570-4</page-range>
            <pub-id pub-id-type="pmid">15148101</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21652.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nesterovitch</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Gyorfy</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Hoffman</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Elbuluk</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Tryniszewska</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Rauch</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Simon</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fisher</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Mikecz</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tharp</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Glant</surname>
                <given-names>TT</given-names>
              </name>
            </person-group>
            <article-title>Alteration in the gene encoding protein tyrosine phosphatase nonreceptor type 6 (PTPN6/SHP1) may contribute to neutrophilic dermatoses.</article-title>
            <source>Am J Pathol</source>
            <year>2011</year>
            <month>Apr</month>
            <volume>178</volume>
            <issue>4</issue>
            <fpage>1434</fpage>
            <page-range>1434-41</page-range>
            <pub-id pub-id-type="pmid">21406173</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21652.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maalouf</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Battistella</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bouaziz</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Neutrophilic dermatosis: disease mechanism and treatment.</article-title>
            <source>Curr Opin Hematol</source>
            <year>2015</year>
            <month>Jan</month>
            <volume>22</volume>
            <issue>1</issue>
            <fpage>23</fpage>
            <page-range>23-9</page-range>
            <pub-id pub-id-type="pmid">25394310</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21652.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wallach</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Vignon-Pennamen</surname>
                <given-names>MD</given-names>
              </name>
            </person-group>
            <article-title>From acute febrile neutrophilic dermatosis to neutrophilic disease: forty years of clinical research.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2006</year>
            <month>Dec</month>
            <volume>55</volume>
            <issue>6</issue>
            <fpage>1066</fpage>
            <page-range>1066-71</page-range>
            <pub-id pub-id-type="pmid">17097401</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21652.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Takahama</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kanbe</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Neutrophilic dermatosis of the dorsal hands: a case showing HLA B54, the marker of Sweet's syndrome.</article-title>
            <source>Int J Dermatol</source>
            <year>2010</year>
            <month>Sep</month>
            <volume>49</volume>
            <issue>9</issue>
            <fpage>1079</fpage>
            <page-range>1079-80</page-range>
            <pub-id pub-id-type="pmid">20883277</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21652.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>von den Driesch</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>MF</given-names>
              </name>
            </person-group>
            <article-title>Are antibodies to neutrophilic cytoplasmic antigens (ANCA) a serologic marker for Sweet's syndrome?</article-title>
            <source>J Am Acad Dermatol</source>
            <year>1993</year>
            <month>Oct</month>
            <volume>29</volume>
            <issue>4</issue>
            <fpage>666</fpage>
            <pub-id pub-id-type="pmid">8408813</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21652.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cohen</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Kurzrock</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Sweet's syndrome revisited: a review of disease concepts.</article-title>
            <source>Int J Dermatol</source>
            <year>2003</year>
            <month>Oct</month>
            <volume>42</volume>
            <issue>10</issue>
            <fpage>761</fpage>
            <page-range>761-78</page-range>
            <pub-id pub-id-type="pmid">14521689</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21652.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sanchez</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Lowenstein</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Babik</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Haag</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Keller</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Ortega-Loayza</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>McCalmont</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Demer</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Mansh</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Hylwa</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Shinkai</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Clinical Features of Neutrophilic Dermatosis Variants Resembling Necrotizing Fasciitis.</article-title>
            <source>JAMA Dermatol</source>
            <year>2019</year>
            <month>Jan</month>
            <day>01</day>
            <volume>155</volume>
            <issue>1</issue>
            <fpage>79</fpage>
            <page-range>79-84</page-range>
            <pub-id pub-id-type="pmid">30383110</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21652.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Surovy</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Pelivani</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hegyi</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Buettiker</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Beltraminelli</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Borradori</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Giant cellulitis-like Sweet Syndrome, a new variant of neutrophilic dermatosis.</article-title>
            <source>JAMA Dermatol</source>
            <year>2013</year>
            <month>Jan</month>
            <volume>149</volume>
            <issue>1</issue>
            <fpage>79</fpage>
            <page-range>79-83</page-range>
            <pub-id pub-id-type="pmid">23324762</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21652.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bamelis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Boyden</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Sente</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Madoe</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Sweet's syndrome and acute myelogenous leukemia in a patient who presented with a sudden massive swelling of the tongue.</article-title>
            <source>Dermatology</source>
            <year>1995</year>
            <volume>190</volume>
            <issue>4</issue>
            <fpage>335</fpage>
            <page-range>335-7</page-range>
            <pub-id pub-id-type="pmid">7655121</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21652.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gottlieb</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Mishra</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Belliveau</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Green</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Heathcote</surname>
                <given-names>JG</given-names>
              </name>
            </person-group>
            <article-title>Ocular involvement in acute febrile neutrophilic dermatosis (Sweet syndrome): new cases and review of the literature.</article-title>
            <source>Surv Ophthalmol</source>
            <year>2008</year>
            <season>May-Jun</season>
            <volume>53</volume>
            <issue>3</issue>
            <fpage>219</fpage>
            <page-range>219-26</page-range>
            <pub-id pub-id-type="pmid">18501268</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21652.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vanourny</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Swick</surname>
                <given-names>BL</given-names>
              </name>
            </person-group>
            <article-title>Sweet syndrome with systemic inflammatory response syndrome.</article-title>
            <source>Arch Dermatol</source>
            <year>2012</year>
            <month>Aug</month>
            <volume>148</volume>
            <issue>8</issue>
            <fpage>969</fpage>
            <page-range>969-70</page-range>
            <pub-id pub-id-type="pmid">22911211</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21652.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Su</surname>
                <given-names>WP</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>HN</given-names>
              </name>
            </person-group>
            <article-title>Diagnostic criteria for Sweet's syndrome.</article-title>
            <source>Cutis</source>
            <year>1986</year>
            <month>Mar</month>
            <volume>37</volume>
            <issue>3</issue>
            <fpage>167</fpage>
            <page-range>167-74</page-range>
            <pub-id pub-id-type="pmid">3514153</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21652.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cohen</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Kurzrock</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Sweet's syndrome: a review of current treatment options.</article-title>
            <source>Am J Clin Dermatol</source>
            <year>2002</year>
            <volume>3</volume>
            <issue>2</issue>
            <fpage>117</fpage>
            <page-range>117-31</page-range>
            <pub-id pub-id-type="pmid">11893223</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21652.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khatri</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Taha</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Sweet's syndrome associated with myelodysplastic syndrome presenting as periorbital cellulitis.</article-title>
            <source>Int J Dermatol</source>
            <year>2007</year>
            <month>May</month>
            <volume>46</volume>
            <issue>5</issue>
            <fpage>496</fpage>
            <page-range>496-9</page-range>
            <pub-id pub-id-type="pmid">17472681</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21652.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Seminario-Vidal</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Guerrero</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sami</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Refractory Sweet's syndrome successfully treated with rituximab.</article-title>
            <source>JAAD Case Rep</source>
            <year>2015</year>
            <month>May</month>
            <volume>1</volume>
            <issue>3</issue>
            <fpage>123</fpage>
            <page-range>123-5</page-range>
            <pub-id pub-id-type="pmid">27051705</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21652.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hashemi</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Fazeli</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Vahedi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Golabchifard</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Rituximab for refractory subcutaneous Sweet's syndrome in chronic lymphocytic leukemia: A case report.</article-title>
            <source>Mol Clin Oncol</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>4</volume>
            <issue>3</issue>
            <fpage>436</fpage>
            <page-range>436-440</page-range>
            <pub-id pub-id-type="pmid">26998300</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21652.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Agarwal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Barrow</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Selim</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Nicholas</surname>
                <given-names>MW</given-names>
              </name>
            </person-group>
            <article-title>Refractory Subcutaneous Sweet Syndrome Treated With Adalimumab.</article-title>
            <source>JAMA Dermatol</source>
            <year>2016</year>
            <month>Jul</month>
            <day>01</day>
            <volume>152</volume>
            <issue>7</issue>
            <fpage>842</fpage>
            <page-range>842-4</page-range>
            <pub-id pub-id-type="pmid">27028556</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21652.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Joshi</surname>
                <given-names>TP</given-names>
              </name>
              <name>
                <surname>Friske</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Hsiou</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Duvic</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>New Practical Aspects of Sweet Syndrome.</article-title>
            <source>Am J Clin Dermatol</source>
            <year>2022</year>
            <month>May</month>
            <volume>23</volume>
            <issue>3</issue>
            <fpage>301</fpage>
            <page-range>301-318</page-range>
            <pub-id pub-id-type="pmid">35157247</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21652.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nousari</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Valenzuela</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Successful use of baricitinib in the treatment of refractory rheumatoid arthritis-associated Sweet syndrome.</article-title>
            <source>Clin Exp Dermatol</source>
            <year>2021</year>
            <month>Oct</month>
            <volume>46</volume>
            <issue>7</issue>
            <fpage>1330</fpage>
            <page-range>1330-1332</page-range>
            <pub-id pub-id-type="pmid">33914946</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21652.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chavan</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Cappel</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Ketterling</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Wada</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Rochet</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Knudson</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gibson</surname>
                <given-names>LE</given-names>
              </name>
            </person-group>
            <article-title>Histiocytoid Sweet syndrome may indicate leukemia cutis: a novel application of fluorescence in situ hybridization.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2014</year>
            <month>Jun</month>
            <volume>70</volume>
            <issue>6</issue>
            <fpage>1021</fpage>
            <page-range>1021-7</page-range>
            <pub-id pub-id-type="pmid">24636890</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21652.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Prat</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bouaziz</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Wallach</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Vignon-Pennamen</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Bagot</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Neutrophilic dermatoses as systemic diseases.</article-title>
            <source>Clin Dermatol</source>
            <year>2014</year>
            <season>May-Jun</season>
            <volume>32</volume>
            <issue>3</issue>
            <fpage>376</fpage>
            <page-range>376-88</page-range>
            <pub-id pub-id-type="pmid">24767185</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21652.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Caucanas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Heylen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rolland</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>M&#x000fc;ller</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Olemans</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sass</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Vanhooteghem</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Associated pyoderma gangrenosum, erythema elevatum diutinum, and Sweet's syndrome: the concept of neutrophilic disease.</article-title>
            <source>Int J Dermatol</source>
            <year>2013</year>
            <month>Oct</month>
            <volume>52</volume>
            <issue>10</issue>
            <fpage>1185</fpage>
            <page-range>1185-8</page-range>
            <pub-id pub-id-type="pmid">24073904</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21652.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jagati</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shrivastava</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Baghela</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Agarwal</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Saikia</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Acquired cutis laxa secondary to Sweet syndrome in a child (Marshall syndrome): A rare case report.</article-title>
            <source>J Cutan Pathol</source>
            <year>2020</year>
            <month>Feb</month>
            <volume>47</volume>
            <issue>2</issue>
            <fpage>146</fpage>
            <page-range>146-149</page-range>
            <pub-id pub-id-type="pmid">31437319</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21652.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wawrzycki</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Chodorowska</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pietrzak</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Krasowska</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>W&#x00105;sik</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dybiec</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lotti</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hercegova</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Recurrent skin eruption in patient with chronic lymphocytic leukemia and lymphocytic infiltrates of the dermis resembling Sweet's syndrome.</article-title>
            <source>G Ital Dermatol Venereol</source>
            <year>2011</year>
            <month>Dec</month>
            <volume>146</volume>
            <issue>6</issue>
            <fpage>487</fpage>
            <page-range>487-92</page-range>
            <pub-id pub-id-type="pmid">22095180</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
